

Legacy Day Treatment Unit Provider's Orders

Adult Ambulatory Infusion Order OCRELIZUMAB (OCREVUS)

Patient Name:		
Date of Birth:		

Med. Rec. No (TVC MRN Only):

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE

Anticipated Start Date: ***This plan will expire after 365 days, Orders expire:		Patient to follow up with provider on date:unless otherwise specified below***	
Weigl	ht:kg Height:	cm	
Allerg	jies:		
Diagn	osis:		
		(please include primary and secondary diagnosis codes)	
	duling instructions: Initial dose atravenous, starting 6 months aft	300 mg, intravenous, x 2 doses, 14 days apart. Maintenance dose 600 er initial dose, every 6 months.	
GUID	ELINES FOR PRESCRIBING:		
	Hepatitis B (Hep B surface ant	ICE CARD and most recent provider chart or progress note. gen and core antibody total) screening must be completed prior to atient should not be infected. Please send results with order.	

☐ Hepatitis B surface antigen and core antibody test results scanned with orders.

NURSING ORDERS (TREATMENT PARAMETERS):

PRE-SCREENING: (Results must be available prior to initiation of therapy)

- 1. TREATMENT PARAMETER Hold treatment and contact provider if Hepatitis B surface antigen or core antibody total test result is positive or if screening has not been performed.
- 2. RN to assess for active infection. If patient shows signs and symptoms of active infection or currently taking antibiotics. Hold treatment and notify provider
- 3. VITAL SIGNS First and second infusions: Obtain vital signs at baseline, then every 30 minutes with rate escalation, then every 30 minutes for the duration of the infusion. Third infusion and beyond: Obtain vital signs at baseline, then every 30 minutes with rate escalation. If no previous infusion reaction, monitor vital signs every hour until infusion complete.
- 4. Monitor patient for Ocrelizumab infusion-related reactions for 1 hour after completion of first and second Ocrelizumab infusions. Monitoring not required for third infusion and beyond, if no previous infusion reactions. Lengthened monitoring recommended for previous infusion reactions, contact provider for guidance
- 5. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes
- 6. Nursing communication order, every visit: Manage line per LH policy 904.4007 IV Catheter Insertion (Peripheral) and LH 904.4004 IV Access: Central Catheters
- 7. Nursing communication order, every visit: Monitor patient for potential adverse effects (ADEs) during and after infusion: ADEs may include hypersensitivity reactions and hypotension.
- 8. Nursing communication orders, every visit: Manage hypersensitivity reactions per LH 906.6606.
- 9. Nursing communication orders, every visit: Monitor for signs and symptoms of hypersensitivity during infusion and 30 minutes following completion



Legacy Day Treatment Unit Provider's Orders

Adult Ambulatory Infusion Order OCRELIZUMAB (OCREVUS)

Patient Name:	
Date of Birth:	
Med. Rec. No (TVC MRN Only):	

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE

PRE-MEDICATIONS: (Administer 30-60 minutes prior to infusion) Note to provider: Please select which medications below, if any, you would like the patient to receive prior to treatment by checking the appropriate box(s)
 □ acetaminophen (TYLENOL) tablet, 650 mg, oral, ONCE, every visit □ diphenhydrAMINE (BENADRYL) capsule, 50 mg, oral, ONCE, every visit. Give either loratadine or diphenhydrAMINE, not both. □ loratadine (CLARITIN) tablet, 10 mg, oral, ONCE AS NEEDED if diphenhydrAMINE is not given, ever visit. Give either loratadine or diphenhydrAMINE, not both. □ methylPREDNISolone sodium succinate (SOLU-MEDROL), 100 mg, intravenous, ONCE, every visit □ Other:, 30 minutes prior to infusion, every visit □ No routine pre-medications
MEDICATIONS: (must check one)
☐ Ocrelizumab (OCREVUS) 300 mg in sodium chloride 0.9%, intravenous Every 2 weeks for 2 treatments
Infuse per infusion plan nursing orders. Infuse through 0.2 micron inline filter. Do not shake
NURSING COMMUNICATION – For 300 mg infusions: Infuse Ocrelizumab via pump slowly a 30 mL/hr for the first half-hour. If no infusion related side effect is seen, increase rate gradually (30 mL/hour) every 30 minutes to a maximum of 180 mL/hour. If infusion not tolerated, STOP infusion, notify provider and administer appropriate hypersensitivity medications. When infusion related side effects have resolved begin the Ocrelizumab infusion at half the previous rate. Resume titrations with provider guidance
☐ Ocrelizumab (OCREVUS) 600 mg in sodium chloride 0.9%, intravenous Every 24 weeks, until discontinued
Infuse per infusion plan nursing orders. Infuse through 0.2 micron inline filter. Do not shake
NURSING COMMUNICATION – For 600 mg infusions: If previous infusion reaction, contact

provider for rate guidance. If no previous infusion related side effects noted, infuse Ocrelizumab via pump at 100 mL/hr for the first 15 minutes. Increase to 200 mL/hr for the next 15 minutes. Increase to 250 mL/hr for the next 30 minutes. Increase to 300 mL/hr for the remaining 60 minutes. If infusion not tolerated STOP infusion, notify provider and administer appropriate hypersensitivity medications. When infusion related side effects have resolved begin the Ocrelizumab infusion at half the previous rate.



Legacy Day Treatment Unit Provider's Orders

Adult Ambulatory Infusion Order OCRELIZUMAB (OCREVUS)

Patient	Name:
Date of	Birth:

Med. Rec. No (TVC MRN Only):

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE

HYPERSENSITIVITY MEDICATIONS:

Organization/Department: ___

- NURSING COMMUNICATION If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Refer to LH policy 906.6606 Initiation of Emergency Measures for Adult Oncology, Radiation Oncology and Infusion Clinic Patients
- 2. acetaminophen (TYLENOL) tablet, 650 mg, oral, EVERY 4 HOURS AS NEEDED for infusion reaction
- 3. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x1 dose for rash, hypersensitivity or infusion reaction
- 4. EPINEPHrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x1 dose for hypersensitivity or infusion reaction
- 5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x1 dose for hypersensitivity or infusion reaction
- 6. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x1 dose for hypersensitivity or infusion reaction
- 7. meperidine (DEMOEROL) injection, 25-50 mg, intravenous, every 2 hours as needed for infusionrelated severe rigors in the absence of hypotension. Not to exceed 50 mg/hr
- 8. sodium chloride 0.9% IV bolus, 1,000 mL, as needed for infusion related side effects

Printed Name:	Phone:	Fax:
Legacy Woodburn STEPS Clinic A department of Silverton Medical Cent Legacy Woodburn Health Center 1475 Mt Hood Ave Woodburn, OR 97071 Phone number: 503-982-1280 Fax number: 503-225-8723 Provider signature:		Time:
Legacy Salmon Creek Day Treatmen Legacy Salmon Creek Medical Center 2121 NE 139 th Street, Suite 110 Vancouver, WA 98686 Phone number: 360-487-1750 Fax number: 360-487-5773	t Unit □	Legacy Silverton STEPS Clinic Legacy Silverton Medical Center 342 Fairview Street Silverton, OR 97381 Phone number: 503-873-1670 Fax number: 503-874-2483
Legacy Day Treatment Unit – The Vancouver Clinic Building A department of Salmon Creek Medica 700 NE 87 th Avenue, Suite 360 Vancouver, WA 98664 Phone number: 360-896-7070 Fax number: 360-487-5773		Legacy Emanuel Day Treatment Unit A department of Emanuel Medical Center 501 N Graham Street, Suite 540 Portland, OR 97227 Phone number: 503-413-4608 Fax number: 503-413-4887
Please check the appropriate box for the patie	ent's preferred clin	ic location:
o. Socium chionae 0.9% iv bolus, 1,000 i	me, as needed for	iniusion related side effects